HALO
Halozyme Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.10B
P/E Ratio
23.97
EPS
$2.85
Beta
0.88
52W High
$82.22
52W Low
$51.06
50-Day MA
$65.75
200-Day MA
$69.12
Dividend Yield
—
Profit Margin
23.10%
Forward P/E
9.46
PEG Ratio
-2.50
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.51B |
| Gross Profit (TTM) | $1.16B |
| EBITDA | $953.01M |
| Operating Margin | 49.00% |
| Return on Equity | 99.40% |
| Return on Assets | 22.10% |
| Revenue/Share (TTM) | $12.72 |
| Book Value | $1.85 |
| Price-to-Book | 36.88 |
| Price-to-Sales (TTM) | 5.37 |
| EV/Revenue | 6.58 |
| EV/EBITDA | 15.91 |
| Quarterly Earnings Growth (YoY) | 31.20% |
| Quarterly Revenue Growth (YoY) | 42.20% |
| Shares Outstanding | $118.61M |
| Float | $117.28M |
| % Insiders | 1.06% |
| % Institutions | 107.63% |
Historical Volatility
HV 10-Day
43.81%
HV 20-Day
34.22%
HV 30-Day
33.02%
HV 60-Day
31.34%
HV Rank
68.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($83.90 target)
2
Strong Buy4
Buy2
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026